ObsEva SA ObsEva appoints industry expert as Chief Medical Officer to further advance its Phase 3 clinical programs

ObsEva SA: ObsEva appoints industry expert as Chief Medical Officer to further advance its Phase 3 clinical programs

Geneva, Switzerland and Boston, MA - July 1, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel...

More From BioPortfolio on "ObsEva SA: ObsEva appoints industry expert as Chief Medical Officer to further advance its Phase 3 clinical programs"